Your browser doesn't support javascript.
loading
Inactivated whole virus particle vaccine with potent immunogenicity and limited IL-6 induction is ideal for influenza.
Sekiya, Toshiki; Mifsud, Edin J; Ohno, Marumi; Nomura, Naoki; Sasada, Mayumi; Fujikura, Daisuke; Daito, Takuji; Shingai, Masashi; Ohara, Yuki; Nishimura, Tomohiro; Endo, Masafumi; Mitsumata, Ryotarou; Ikeda, Tomio; Hatanaka, Hironori; Kitayama, Hiroki; Motokawa, Kenji; Sobue, Tomoyoshi; Suzuki, Saori; Itoh, Yasushi; Brown, Lorena E; Ogasawara, Kazumasa; Kino, Yoichiro; Kida, Hiroshi.
Afiliação
  • Sekiya T; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE) Hokkaido University, Sapporo, Japan; The Department of Microbiology and Immunology, The University of Melbourne at the
  • Mifsud EJ; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE) Hokkaido University, Sapporo, Japan; The Department of Microbiology and Immunology, The University of Melbourne at the
  • Ohno M; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Nomura N; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Sasada M; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Fujikura D; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Daito T; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Shingai M; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE) Hokkaido University, Sapporo, Japan.
  • Ohara Y; KM Biologics Co. Ltd., Kumamoto, Japan.
  • Nishimura T; KM Biologics Co. Ltd., Kumamoto, Japan.
  • Endo M; KM Biologics Co. Ltd., Kumamoto, Japan.
  • Mitsumata R; R&D Center, Denka Seiken Co., Ltd., Niigata, Japan.
  • Ikeda T; R&D Center, Denka Seiken Co., Ltd., Niigata, Japan.
  • Hatanaka H; The Research Foundation for Microbial Diseases of Osaka University, Kannonji, Kagawa, Japan.
  • Kitayama H; The Research Foundation for Microbial Diseases of Osaka University, Kannonji, Kagawa, Japan.
  • Motokawa K; Manufacturing Department III, Kitasato Daiichi Sankyo Vaccine Co. Ltd., Saitama, Japan.
  • Sobue T; CMC Research Laboratories, Kitasato Daiichi Sankyo Vaccine Co. Ltd., Saitama, Japan.
  • Suzuki S; Division of Pathology and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan.
  • Itoh Y; Division of Pathology and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan.
  • Brown LE; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE) Hokkaido University, Sapporo, Japan; The Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Ogasawara K; Division of Pathology and Disease Regulation, Department of Pathology, Shiga University of Medical Science, Otsu, Japan; Research Center for Animal Life Science, Shiga University of Medical Science, Otsu, Japan.
  • Kino Y; Kino Consulting, Kumamoto, Japan.
  • Kida H; Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan; Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE) Hokkaido University, Sapporo, Japan; Collaborating Research Center for the Control of Infectious Diseases, Nagasaki Un
Vaccine ; 37(15): 2158-2166, 2019 04 03.
Article em En | MEDLINE | ID: mdl-30857932
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Vírion / Vacinas contra Influenza / Interleucina-6 / Infecções por Orthomyxoviridae / Anticorpos Antivirais Limite: Animals / Female / Humans / Male País/Região como assunto: Asia Idioma: En Revista: Vaccine Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Vírion / Vacinas contra Influenza / Interleucina-6 / Infecções por Orthomyxoviridae / Anticorpos Antivirais Limite: Animals / Female / Humans / Male País/Região como assunto: Asia Idioma: En Revista: Vaccine Ano de publicação: 2019 Tipo de documento: Article